Amgen's Sotorasib Granted Breakthrough Therapy Designation for Advanced or Metastatic Non-Small Cell Lung Cancer Patients with KRAS G12C Mutation
Sotorasib Also Accepted Into FDA's Real-Time Oncology Review Pilot Program
New Drug Application Submission to FDA Planned by End of the Year
THOUSAND OAKS, Calif., Dec. 8, 2020 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today ... Biopharmaceuticals, Oncology, FDA Amgen, Sotorasib, Non-Small Cell Lung Cancer, KRAS
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Marketing | New Drug Applications | Non-Small Cell Lung Cancer | Pharmaceuticals